Palatin Technologies (PTN)
(Delayed Data from AMEX)
$1.58 USD
-0.11 (-6.51%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.57 -0.01 (-0.63%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PTN 1.58 -0.11(-6.51%)
Will PTN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTN
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
PTN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates
Other News for PTN
Palatin files to sell 4.85M shares of common stock for holders
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
Palatin Technologies Secures Growth with Warrant Exercise Deal
Palatin exercises warrants for gross proceeds of ~$6.1M
Buy Rating Affirmed for Palatin Technologies Amid Promising ED and Obesity Treatment Trials